Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amarin CEO Refuses to Discuss Drug Patent Issues Killing His Stock Price
Amarin CEO Refuses to Discuss Drug Patent Issues Killing His Stock Price
Amarin CEO Refuses to Discuss Drug Patent Issues Killing His Stock Price
Submitted by
admin
on November 9, 2011 - 9:13am
Source:
TheStreet.com
News Tags:
Amarin
Joe Zakrzewski
patents
AMR101
Headline:
Amarin CEO Refuses to Discuss Drug Patent Issues Killing His Stock Price
Do Not Allow Advertisers to Use My Personal information
